NEW YORK (GenomeWeb News) – Trovagene today announced it has granted Duke University and Duke University Health Systems a non-exclusive license covering the use of the nucleophosmin protein (NPM1).
The agreement allows Duke to incorporate NPM1 into research and clinical testing services for acute myelogenous leukemia. The terms of the deal includes upfront payments and royalties. Further details were not disclosed.
Trovagene holds the exclusive worldwide license to the patent around NPM1. Duke is the latest licensee of the technology. Last week, Trovagene said that Genoptix licensed rights to use NPM1, and others that have sublicensed the protein include Quest Diagnostics, Laboratory Corporation of America, and Münchner Leukamielabor in Germany.
Trovagene also has co-licensing deals with Asuragen and Ipsogen, part of Qiagen, to manufacture and sell NPM1 mutation kits.